AIHC, the Tuttle Capital AI Drug Discovery ETF, is an ETF whose main story is the biology trade.
Key facts
Against its peers
Nearest by size
The ETFs ranked just above and below AIHC by assets, among the 82 ETFs whose main narrative is the biology trade, largest first.
| # | ETF | SHARE | ASSETS | 1 YEAR | COST |
|---|---|---|---|---|---|
| 72 | LGHT | under 0.1% | $2.4m | +4.3% | 0.85% |
| 73 | BIS | – | $1.9m | −49.3% | 0.95% |
| 74 | YUNG | under 0.1% | $929,401 | – | 0.35% |
| 75 | GSKH | under 0.1% | $682,763 | +18.9% | 0.19% |
| 76 | XLVX | under 0.1% | $647,180 | – | 0.45% |
| 77 | TEMC | under 0.1% | $541,370 | – | 0.45% |
| 78 | XBIX | under 0.1% | $535,941 | – | 0.45% |
| 79 | HIMC | under 0.1% | $229,654 | – | 0.45% |
| 80 | NVOC | under 0.1% | $213,115 | – | 0.45% |
| 81 | AIHC | – | – | – | – |
| 82 | PEPT | – | – | – | 0.65% |
Share is each ETF’s slice of the money in ETFs carrying this narrative. 1 year is price change plus dividends; cost is the yearly fee.
The narrative it carries
This is its only narrative.
The biology trade →
Health care from drugmakers and insurers to genomics: the science that gets approved, and who pays for it.
This week its attention level is 46.7, in the WARM band, 19th of 22. 91 ETFs carry it.
How it is built
A plain ETF that owns its holdings directly. It counts toward its narrative's share of money.
Common questions
What story is AIHC selling?
AIHC’s main story is the biology trade, which covers health care from drugmakers and insurers to genomics: the science that gets approved, and who pays for it.
Is AIHC leveraged?
No. AIHC is a plain ETF: it aims to move one for one with what it holds.
Run an ETF in the biology trade? StoryVector shows issuers where their ETFs stand against the closest rivals, every week.
Request a pilot